Dr. Yujie PU
|
 |
| SCI-indexed publications |
- Pu Y, Cheng CK, Zhang H, Luo J, Wang L, Tomlinson T, Huang Y (2023) Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor α agonists in cardiovascular health and diseases. Medicinal Research Reviews 43(6):2086-2114.
- Dong P, Huang Y, Pu Y (2023) The therapeutic effects of ligustrazine in combination with other drugs in cardiovascular diseases. International Journal of Drug Discovery and Pharmacology 2(1):64-69.
- Cheng CK, Lin X, Pu Y, Tse KYJ, Wang Y, Zhang CL, Cao X, Lau CW, Huang J, He L, Luo JY, Shih YT, Wan S, Ng CF, Wang L, Ma CWR, JJ Chiu, Chan TF, Tian XY & Huang Y (2023) SOX4 is a novel phenotypic regulator of endothelial cells in atherosclerosis revealed by single-cell analysis. Journal of Advanced Research 43:187-203.
- Luo JY, Cheng CK, He L, Pu Y, Zhang Y, Lin X, Xu A, Lau CW, Tian XY, Ma RCW, Jo H & *Huang Y (2022) Endothelial UCP2 is a mechanosensitive suppressor of atherosclerosis. Circulation Research 131(5):424-441.
-
Huang J, Pu Y, Zhang H, Xie L, He L, Zhang C, Cheng CK, Huo Y, Wan S, Chen S, Huang Y, Lau CW, Wang L, Xia Yin, Huang Y & Luo JY (2021) Endothelial KLF2 mediates the suppressive effect of laminar flow on vascular calcification by inhibiting BMP/SMAD1/5 signaling. Circulation Research 129(4):e87-e100. (Co-first author)
|
|
